Catalog No.S1802 Synonyms: NSC105823
Molecular Weight(MW): 258.23
AICAR (Acadesine), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.
4 Customer Reviews
Cultured hepatocytes were treated with 10 μM Compound C (Comp.C) for 30 min before treatment with 10 μM SAL, 1 mM AICAR for 3 h. Cell lysates were immunoblotted for the phosphorylation of AMPK, ACC, Akt and GSK3β. *P < 0.05, **P < 0.01 versus control; ##P < 0.01 versus SAL alone; †P < 0.05, ††P < 0.01 versus AICAR alone. Values are means ± SEM (n = 4).
British Journal of Pharmacology, 2015, 172(13):3284–3301.. AICAR (Acadesine) purchased from Selleck.
Activation of AMPK with AICAR reduced INH-caused inhibition of mitochondrial biogenesis by activation of SIRT1-PGC1α pathway. HepG2 cells were exposed to INH (60mM) for 24 h in the presence or absence of an AMPK activator AICAR (0.095 mM). Expressions of PGC1α, NRF1 and COX IV (B) were analyzed by western blotting.
J Appl Toxicol, 2017, 37(10):1219-1224. AICAR (Acadesine) purchased from Selleck.
Relative StAR (D) mRNAs levels in granulosa cells cultured for 4 h in the absence or presence of 10 ng/ml FSH, or together with AMPK activator (1 mM AICAR). Relative expression level was normalized to 18S rRNA. Data are expressed as fold differences ± SEM of three independent experiments using tissues from different hens and are compared to control cells. *, P < 0.05 compared to control cells; #, P < 0.05 compared to cells only stimulated by 10 ng/ml FSH.
PLoS One, 2017, 12(1):e0170409. AICAR (Acadesine) purchased from Selleck.
Purity & Quality Control
Choose Selective AMPK Inhibitors
|Description||AICAR (Acadesine), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.|
|Features||A potential first-in-class adenosine regulating agent (ARA).|
Acadesine (500 μM) increases the ZMP content in extracts of isolated hepatocytes after up to 30-40 min treatment, then remains fairly constant at approximately 4 nmol/g. Acadesine (500 μM) causes a transient 12-fold activation of AMPK at 15 min in rat hepatocytes and 2-3 fold activation of AMPK in adipocytes, without affecting levels of ATP, ADP or AMP. Acadesine (500 μM) causes a dramatic inhibition of both fatty acid and sterol synthesis in rat hepatocytes. Acadesine (500 μM) also causes a dramatic inactivation of HMG-CoA reductase.  Acadesine induces apoptosis of B-CLL cells in a dose-dependent manner with EC50 of 380 μM. Acadesine (0.5 mM) decreases cell viability of B-CLL cells from 20 representative patients from 68% to 26%. Acadesine (0.5 mM) induces caspase activation and cytochrome crelease from mitochondria. Uptake and phosphorylation of Acadesine (0.5 mM) are required to induce apoptosis and activate AMPK in B-CLL cells. Acadesine (2-4 mM) only slightly affects the viability of T cells from B-CLL patients, Acadesine (0.5 mM) remarkedly reduces viability of B cells but not T cells.  Acadesine triggers loss of cell metabolism in K562, LAMA-84 and JURL-MK1 and is also effective in killing imatinib-resistant K562 cells and Ba/F3 cells carrying the T315I-BCR-ABL mutation. The effect of Acadesine is abrogated by GF109203X and Ro-32-0432, both inhibitor of classical and new PKCs and accordingly, Acadesine triggers relocation and activation of several PKC isoforms in K562 cells. Acadesine dose-dependently inhibits K562 colony formation at day 10, the growth inhibitory effect of acadesine is already detected at 0.25 mM and is maximal at 2.5 mM.  Acadesine causes a concentration-related reduction in CD18 expression on LPS-stimulated neutrophils in vitro.  Acadesine significantly (1 mM) inhibits N-formyl-methionyl-leucyl-phenylalanine-induced granulocyte CD11b up-regulation by a mean of 61% in blood. 
|In vivo||Acadesine (50 mg/kg) significantly reduces tumor formation in a mouse xenograft model of K562 cells.  Acadesine (10 mg/kg) results in higher fluid required to stabilize hemodynamics in pigs. Acadesine (10 mg/kg) inhibits LPS-induced protein permeability of pulmonary capillaries, peak inspiratory pressures on constant tidal volume and dead space ventilation in pigs. |
|In vitro||DMSO||51 mg/mL (197.49 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01813838||Terminated||SMD||Groupe Francophone des Myelodysplasies|Advancell - Advanced In Vitro Cell Technologies, S.A.||June 2013||Phase 1|Phase 2|
|NCT00872001||Terminated||Coronary Artery Bypass|Myocardial Infarction|Ventricular Dysfunction, Left|Stroke|Cardiopulmonary Bypass||Merck Sharp & Dohme Corp.|Duke Clinical Research Institute||April 2009||Phase 3|
|NCT00559624||Completed||Leukemia, B-Cell, Chronic||Advancell - Advanced In Vitro Cell Technologies, S.A.|Nexus Oncology Ltd||December 2007||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.